Charles River Laboratories International (NYSE:CRL) Upgraded by Redburn Atlantic to "Buy" Rating

Redburn Atlantic upgraded shares of Charles River Laboratories International (NYSE:CRL - Free Report) from a neutral rating to a buy rating in a research report released on Friday, MarketBeat.com reports. The brokerage currently has $182.00 price target on the medical research company's stock, down from their previous price target of $188.00.

Other research analysts also recently issued reports about the company. Robert W. Baird raised their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price target for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Evercore ISI raised shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective for the company in a research note on Thursday, May 8th. Barclays raised their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. Finally, Mizuho lowered their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $171.85.

Charles River Laboratories International Trading Up 0.9%

Shares of CRL traded up $1.16 during trading hours on Friday, reaching $136.76. 775,603 shares of the company traded hands, compared to its average volume of 993,966. The stock's fifty day moving average price is $132.05 and its 200 day moving average price is $162.77. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of 911.73, a PEG ratio of 4.54 and a beta of 1.50. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the business posted $2.27 EPS. Sell-side analysts forecast that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.30% of the company's stock.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds have recently modified their holdings of the stock. Veracity Capital LLC purchased a new stake in Charles River Laboratories International during the 4th quarter worth approximately $589,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at $237,000. Blue Trust Inc. grew its holdings in shares of Charles River Laboratories International by 7.8% during the fourth quarter. Blue Trust Inc. now owns 2,023 shares of the medical research company's stock valued at $398,000 after buying an additional 146 shares during the last quarter. KBC Group NV increased its position in shares of Charles River Laboratories International by 0.9% in the 4th quarter. KBC Group NV now owns 85,362 shares of the medical research company's stock valued at $15,758,000 after acquiring an additional 796 shares during the period. Finally, Robeco Institutional Asset Management B.V. raised its stake in Charles River Laboratories International by 3.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 4,354 shares of the medical research company's stock worth $804,000 after acquiring an additional 126 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).